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Abstract
Neural stem/progenitor cells (NSPCs) have the ability to migrate into the central nervous system (CNS) to replace
damaged cells. In inflammatory CNS disease, cytokine transduced neural stem cells may be used as vehicles to
specifically reduce inflammation and promote cell replacement. In this study, we used NSPCs overexpressing IL-10,
an immunomodulatory cytokine, in an animal model for CNS inflammation and multiple sclerosis (MS). Intravenous
injection of IL-10 transduced neural stem/progenitor cells (NSPCIL-10) suppressed myelin oligodendrocyte glycoprotein
aa 35–55 (MOG35-55)- induced experimental autoimmune encephalomyelitis (EAE) and, following intravenous
injection, NSPCIL-10 migrated to peripheral lymphoid organs and into the CNS. NSPCIL-10 suppressed antigen-specific
proliferation and proinflammatory cytokine production of lymph node cells obtained from MOG35-55 peptide
immunized mice. In this model, IL-10 producing NSPCs act via a peripheral immunosuppressive effect to attenuate EAE.
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Highlights
 Intravenous injected NSPCIL-10 suppress EAE.
 NSPCIL-10 migrate to lymph nodes, spleen and into
the CNS.
 NSPCIL-10 inhibit T-cell activation, proliferation and
cytokine production.
 This inhibitory effect is independent of indoleamine
2,3-dioxygenase (IDO) and the induction of apoptosis.
Introduction
Multiple sclerosis (MS) is a disabling inflammatory dis-
ease of the central nervous system (CNS) characterized
by inflammation, demyelination and neurodegeneration
[1]. It is the major disabling disease affecting young indi-
viduals. Symptoms such as visual impairment, sensory
disturbances and paralysis depend on the location of
the lesions in the CNS [2]. Current approved therapies
are immunomodulating and immunosuppressive drugs,
including IFN-β, natalizumab, fingolimod, glatiramer
acetate, mitoxantrone and teriflunomide.
A promising method for a comprehensive therapy of
MS integrating various possible therapeutic mechanisms
might be the treatment with neural stem/progenitor cells
(NSPCs). Early work demonstrated the ability of neural
stem cells to proliferate and differentiate into neurons,
oligodendrocytes and astrocytes [3-5], and to display an
inherent tropism for neuropathology [6]. It has been
shown in experimental autoimmune encephalomyelitis
(EAE), the animal model of MS, that transplantation of
neural stem cells promotes remyelination and reduces
brain inflammation [7,8].
NSPCs have been transplanted into recipient animals
to replace injured or damaged neural tissue. This has
been evaluated in various models of degenerative and in-
flammatory CNS diseases [9]. Neural stem cells migrate
into areas of neuropathology such as malignant glioma
[10], brain injury [11] and inflamed CNS tissue during
EAE [8,12]. Moreover, neural stem cells have been
shown to be able to inhibit inflammation within the
CNS in EAE immunized mice [13].
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Taking into account this unique pathotropism, we as-
sumed that NSPCs could be used as a cell-based delivery
model for immunomodulatory molecules. We choose to
use IL-10 as an immunomodulatory cytokine to be deliv-
ered by NSPCs into the CNS of mice immunized to
develop EAE.
IL-10, a regulatory cytokine mainly produced by T-
helper type 2 (Th2) cells, inhibits the activity of Th1 and
Th17 cells, the production of proinflammatory cytokines,
including TNFα, IL-1 and IFN-γ, and chemokines, as well
as the expression of major histocompatibility complex
(MHC) class II molecules by antigen-presenting cells
(APCs) [14-16]. IL-10 also inhibits macrophages and
monocytes, and enhances antibody production and sur-
vival of B-lymphocytes [16]. IL-10-deficient mice develop
more severe EAE than wild-type mice, overexpression of
IL-10 protects mice from EAE [17] and subcutaneous or
intranasal treatment reduces disease severity [18]. Thus,
IL-10 is an efficient anti-inflammatory cytokine which po-
tently suppresses EAE and is therefore a suitable candidate
molecule to be used in our approach. In addition, the im-
munomodulatory capacity of IFN-β treatment in patients
with MS is mediated at least in part by induction of IL-10
production by immune cells.
In this study, we demonstrate that the intravenous in-
jection of IL-10 producing NSPCs in myelin oligo-
dendrocyte glycoprotein aa 35–55 (MOG35-55) peptide
immunized C57BL/6 mice during the initial phase of
EAE resulted in an attenuated disease course. NSPCs
migrated to peripheral lymphoid organs as well as into
the CNS, and inhibited proliferation and production of
proinflammatory cytokines by autoreactive T-cells. Intra-
venous injection of IL-10 producing NSPCs attenuates
EAE via a peripheral immunosuppressive effect poten-
tially via immunosuppression within the CNS.
Materials and methods
Murine NSPCs
NSPCs were established from the frontoparietal brains of
2-week-old C57BL/6 mice and characterized as previously
described [19]. NSPCIL-10 was established by retroviral
transduction with pMSCV-IL10 using a commercially
available kit (MSCV Retroviral Expression System, BD
Biosciences, San Jose, CA, USA).
The cells were grown as neurospheres in complete
NSPC growth medium containing neurobasal medium
(Gibco, Karlsruhe, Germany) supplemented with 100 μg/
mL penicillin/streptomycin (Gibco), 10 mM L-glutamine
(Gibco), 20 μL/mL B-27 supplement (Gibco) and
0.25 μg/mL fungizone (Gibco). Recombinant epidermal
growth factor (EGF) (20 ng/mL, PeproTech, London,
UK), recombinant basic fibroblast growth factor (FGF)
(20 ng/mL, PeproTech) and heparin (1000 IE, Braun,
Melsungen, Germany) were added directly to the tissue
culture flasks twice a week. NSPCs were routinely
harvested and mechanically dissociated into a single cell
suspension when the neurospheres reached 200 to
500 mm. Single cell suspensions were used for further
passages, intravenous injections and in vitro experi-
ments. Supernatants were collected and stored at −80°C
for further experiments.
Animals, EAE induction and NSPC injection
Female C57BL/6 mice were obtained from Charles River
(Sulzfeld, Germany) and housed under pathogen-free
conditions at the animal facility of the Hertie-Institute
for Clinical Brain Research (Tübingen, Germany). All ex-
periments were carried out in accordance with local
regulations and approval was obtained in advance
(Regierungspräsidium Tübingen, animal experimentation
protocol TV N9/04 to BG). At the age of 5 to 6 weeks,
mice were immunized with 60 μg MOG35-55, dissolved
in 100 μL PBS (PAA Laboratories, Pasching, Austria)
and emulsified with 100 μL incomplete Freund’s ad-
juvant (IFA) (Sigma-Aldrich, Steinheim, Germany)
containing 400 μg Mycobacterium tuberculosis (Difco
Laboratories, Detroit, MI, USA). On the day of immuni-
zation and 2 days after immunization, 150 ng Bordetella
pertussis toxin (Merck, Darmstadt, Germany) was
injected intravenously. NSPCIL-10, NSPCs or PBS as a
negative control was injected intravenously on day 7
post-immunization, or on first sign of disease (1 × 106
cells per injection).
For immunization of 2D2 mice, female 2D2 TCR
transgenic mice were obtained from Dr Bettelli [20] and
housed under specific pathogen-free conditions. Mice
aged 5 to 6 weeks were immunized with 25 μg MOG35-
55 dissolved in 100 μL PBS and emulsified with 100 μL
IFA containing 400 μgM tuberculosis. On day 0 and day
2 pi, 150 ng B pertussis toxin was injected intravenously.
At day 5 post-immunization, 1 × 106 NSPCIL10, NSPCs
or PBS was injected intravenously. As a result of the
MOG antigen-specific TCR, 2D2 transgenic mice are
more sensitive to MOG-specific immunization. There-
fore, only a concentration of 25 μg MOG35-55 was used
for immunization. At 14 days post-immunization, cells
were isolated from draining lymph nodes and cultured
in RPMI 1640 medium containing 5 μg/mL or 50 μg/mL
MOG35-55 peptide. Proliferation was determined after
72 hours by 3H-thymidine incorporation as previously
described [21]. Cytokine concentrations in culture super-
natants were measured after 48 hours by enzyme-linked
immunosorbent assay (ELISA) (eBioscience, San Diego,
CA, USA).
Animals were monitored daily starting at least at day 5
post-immunization and clinical signs scored as follows:
0, no paralysis; 1, limp tail; 2, limp tail and weak gait; 3,
hind limb paralysis; 4, fore limb paralysis; and 5, death.
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Histology
Prior to injection, NSPCs were labeled with 4 × 106
molar PKH26 dye for 5 minutes at room temperature.
Dye reaction was stopped with RPMI 1640 medium
containing FBS; cells were washed and injected as previ-
ously described. Two weeks after immunization, brain
tissue and spinal cord were isolated, fixed with 4% para-
formaldehyde (PFA) for 24 hours, incubated for 24 hours
in 20 sucrose and frozen in liquid nitrogen. Spleen,
lymph nodes, liver and lungs were immediately frozen in
liquid nitrogen. Frozen sections were stained with
mounting medium containing DAPI (Linaris, Wertheim,
Germany) and analyzed for PKH26-labeled cells by
fluorescence microscopy. In addition, brain sections
were stained with hematoxylin and eosin (H&E), and an-
alyzed by microscopy.
Spleen cell cultures
Spleens from naive 2D2 TCR transgenic mice and
C57BL/6 mice were isolated and cultured with RPMI
1640 medium containing 0.5 μg/mL, 5 μg/mL or 50 μg/
mL MOG35-55 peptide, or 0.5 μg/mL or 1 μg/mL con-
canavalin A (ConA) in the presence of NSPCIL-10 or
NSPC culture supernatants. To assess effects of NSPC
co-cultivation, isolated naive 2D2 or C57BL/6 spleen
cells were cultured with NSPCIL-10 or NSPCs at a
NSPC/spleen cell ratio of 1:1, 1:10 or 1:100 in RPMI
1640 medium containing 5 μg/mL MOG35-55 or 1 μg/
ml ConA. Proliferation after 72 hours was detected by a
3H-thymidine incorporation assay. Supernatants were
collected after 48 hours, and IL-17, IL-2 and IFN-γ con-
centrations were measured by ELISA. Neurobasal medium
served as a control.
ELISA
Cytokine concentrations were measured by ELISA
according to the manufacturer’s instructions (IL-2, IL-10
and IFN-γ, BD Biosciences; IL-17, eBioscience). ELISA
plates (NUNC, Kamstrupvej, Denmark) were coated
overnight with capture antibody diluted in coating buffer
(0.2 M sodium phosphate, pH 6.5). After 1 hour of
blocking with assay diluent (PBS containing 10% FBS),
cytokine-containing supernatants (eventually diluted
with assay diluent) were incubated for 2 hours, followed
by 1 hour of incubation with biotinylated secondary
antibody and streptavidin-peroxidase. Plates were devel-
oped using 3,3’5,5’-tetramethylbenzidine (TMB) (Sigma-
Aldrich). Reaction was stopped with 1 M hydrogen
chloride and plates were measured at 450 nm using the
microplate reader Multiskan Ex (Thermo, Waltham,
MA, USA). Standard curves were calculated based on
measurements of different concentrations of recombin-
ant cytokines. Plates were washed with PBS containing
0.02% Tween 20 (Roth, Karlsruhe, Germany). All steps
were performed at room temperature, except for the
coating (4°C).
ELISPOT
The IL-10 enzyme-linked immunosorbent spot (ELISPOT)
was performed using a commercially available kit (Human
IL-10 ELISPOT Ready-SET-Go!, eBioscience). Multiscreen
TM-HA plates (Millipore, Billerica, MA, USA) were coated
overnight with coating antibody diluted in coating buffer.
After 1 hour of blocking with RPMI 1640 medium, 4 × 105
NSPCIL-10 or NSPCs were incubated at 37°C, 5% CO2 for
48 hours. Plates were incubated with biotinylated se-
condary antibody for 2 hours and subsequently with
streptavidin-peroxidase for 45 minutes, and then developed
with AEC substrate solution (0.1 M acetate solution,
pH 5.0) for 60 minutes. Resulting spots were analyzed with
an ELISPOT reader. At every step, the plates were washed
with PBS containing 0.02% Tween 20. All steps were
performed at room temperature, except for the coating
with the capture antibody (4°C).
RT-PCR
Total RNA was isolated from spleen cells of naive
C57BL/6 mice or from cultured NSPCIL-10 and NSPCs
(using a kit from Seqlab, Göttingen, Germany). RNA
was transcribed into cDNA using products from
Promega (Madison, WI, USA). PCR reactions were
performed in a thermocycler (Biozym, Oldendorf,
Germany) using the following conditions: 35 cycles for
1 minute at 94°C, 2 minutes at 55°C and 3 minutes at
72°C. Reaction was completed by incubation at 72°C for
10 minutes. PCR products were separated by gel electro-
phoresis using 2% agarose gels containing ethidium
bromide. PCR primers specific for mouse indoleamine
2,3-dioxygenase (IDO) were 5’GCCCACCGGAACTTCC
TTT3’ (forward) and 5’CACTCGTTATAAGCTTTCGT
CAAGTC 3’ (reverse). Amplification of β-actin served as
a control. PCR primers for mouse β-actin were
5’TGTCCACCTTCCAGCAGATGT 3’ (forward) and
5’AGCTCAGTAACAGTCCGCCTAGA 3’ (reverse) [22].
IDO inhibition assays
1-methyl-DL-tryptophan (1-MT) (Sigma-Aldrich) was
used as an IDO inhibitor. Isolated 2D2 spleen cells were
cultured in RPMI 1640 medium containing 5 μg/mL
MOG35-55 and NSPCIL-10 or NSPCs (NSPC/spleen cell
ratio of 1:1) in the presence or absence of 500 μg/mL 1-
MT. Proliferation after 72 hours was detected by 3H-
thymidine incorporation.
Statistical analysis
EAE experiments with NSPC injection on day 7 after
EAE induction were performed with 15 mice per group
and EAE experiments with NSPC injection after onset of
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clinical symptoms with seven mice per group. Prolifera-
tion, ELISA and flow cytometry experiments were car-
ried out in triplicate. Values are expressed as mean ± SD.
Statistical analysis was performed with SPSS Statistics
17.0 for Windows (IBM Armonk, NY, USA). For the
EAE experiments, a survival analysis and analysis of
variance (ANOVA) with a post-hoc Tukey-Kramer test
were performed. In vitro experiments were analyzed
using ANOVA with post-hoc Bonferroni testing.
Results
NSPC culture
NSPCs were cultured in the presence of basic FGF and
EGF from neurospheres (Figure 1a). As expected, pheno-
typic characterization by flow cytometry showed
multipotency of NSPCs and a percentage of neuronal
stem cells among total NSPCs of around 5% (O4- PSA-
NCAM- CD81- Prominin-1) [19,23]. IL-10 production of
transduced cells was confirmed using an IL-10 ELISPOT
assay and an IL-10 ELISA (Figure 1b,c). NSPCs and
NSPCIL-10 were indistinguishable with regard to expres-
sion of differentiation markers (90% expressed CD81,
<10% expressed O4 and PSA-NCAM, 10% expressed
CD133, and 20% expressed A2B5 (Figure 1d).
Injected NSPCIL-10 suppress EAE when injected during
peripheral T-cell activation
To analyze the effect of NSPCIL-10 on the development
of CNS-directed autoimmunity, 1 × 106 NSPCIL-10 was
injected intravenously into C57BL/6 mice on day 7 after
EAE induction with MOG35-55 peptide. Disease severity
and maximum EAE disease score were reduced in mice
that received NSPCIL-10 compared to NSPC- or PBS-
treated control animals. The mean maximum disease score
in NSPCIL-10-treated mice was significantly reduced in
comparison to NSPC-treated mice or PBS-treated control
animals (P = 0.02). Furthermore, NSPCIL-10-treated mice
showed a milder EAE disease score during the whole ob-
servation period and the lowest sum score in comparison
with control groups (Figure 2a). The effects of NSPCIL-10
injection after disease onset were also examined. Injection
of 1 × 106 NSPCIL-10 into MOG35-55 immunized C57BL/
6 mice 1 day after the beginning of clinical EAE only mildly
influenced the disease course (Figure 2a).
In order to assess how NSPCIL-10 exerts suppressive
effects in vivo, we determined their migratory properties
after intravenous injection into immunized animals.
Mice with MOG35-55-induced EAE received intraven-
ous injections of NSPCIL-10 and NSPCs labeled with the
fluorescent dye PKH26. Two weeks after injection,
PKH26+ NSPCIL-10 and NSPCs were present in lungs,
lymph nodes and inflammatory infiltrates within the
CNS (Figure 2b), while no PKH26-labeled NSPCIL-10 or
NSPCs could be detected within the liver.
NSPCIL-10 suppress T-cell proliferation and cytokine
production in draining lymph nodes
MOG35-55-induced EAE is a T-cell-mediated disease,
and autoreactive T-cells in EAE are activated within per-
ipheral lymph nodes before they migrate into the CNS
Figure 1 NSPC and IL-10 production. (a) Morphology of neurospheres as demonstrated by a phase contrast image of a representative neurosphere
culture in presence of 20 ng/mL FGF-2 and 20 ng/mL EGF. (b) IL-10 production of NSPCIL-10 and NSPCs was determined by IL-10 ELISPOT assay (dots
indicating IL-10 producing cells), and (c) IL-10 ELISA. *t-test, P <0.001. (d) Analysis of NSPCIL-10 (black bar) and NSPCs (grey bar) for expression of different
stem cell markers by flow cytometry. EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-linked immunosorbent
spot; FGF, fibroblast growth factor; IL, interleukin; NSPC, neural stem/progenitor cell; PSA-NCAM, polysialic acid neural cell adhesion molecule.
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[24]. Since intravenously injected NSPCIL-10 migrate to per-
ipheral lymph nodes, we considered whether NSPCIL-10
influence the activity or function of autoreactive T-
cells within this compartment. To this end, C57BL/6
mice carrying a transgenic TCR specific for MOG35-55
(2D2 mice) [20] were immunized with MOG35-55 and
treated 7 days following immunization with NSPCIL-10
or PBS. Draining lymph node cells were isolated 14 days
post-immunization, and assessed for proliferation and
cytokine production upon stimulation with MOG35-55
peptide. Treatment with NSPCIL-10 reduced the prolifer-
ative capacity of autoreactive T-cells in draining lymph
nodes (Figure 3a) in this transgenic model. In addition,
the capacity to produce IFN-γ was reduced in treated
animals; IL-17 and IL-10 were only detected at low
levels under these experimental conditions (Figure 3b).
Figure 2 NSPCIL-10 suppress clinical scores in EAE. EAE was induced in C57BL/6 mice by subcutaneous injection of 50 μg MOG35-55 peptide
in CFA plus intravenous injection of 150 ng Bordetella pertussis toxin. (a) On day 7 after EAE induction or (a) after established EAE disease, mice
were intravenously injected with 1 x 106 NSPCIL-10, NSPCs or PBS as indicated. (b) 1 x 106 PKH26-labeled NSPCIL-10, NSPCs or PBS were injected
7 days after induction of EAE in 2D2 mice with MOG35-55. On day 7 after injection, organs were examined by fluorescence microscopy for the
presence of PKH26+ cells. Cell nuclei were stained with DAPI (blue). Infiltration was analyzed by H&E stain. NSPCIL-10 and NSPCs were detected
within lungs, spinal cords, lymph nodes and brains of MOG35-55 immunized 2D2 mice and in the CNS within cellular infiltrates. Tissues are
shown from NSPCIL-10-treated mice as representative examples for NSPC- and NSPCIL-10-treated mice. CFA, complete Freund’s adjuvant; CNS,
central nervous system; DAPI, 4’,6-diamidino-2-phenylindole; EAE, experimental autoimmune encephalomyelitis; H&E, hematoxylin and eosin; IL,
interleukin; MOG35-55, myelin oligodendrocyte glycoprotein aa 35–55; NSPC, neural stem/progenitor cell; PBS, phosphate-buffered saline.
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Transferred NSPCIL-10 thus inhibited proliferation and
IFN-γ production by autoreactive T-cells at the site of
peripheral T-cell activation in vivo.
Immunosuppressive effects of NSPCIL-10 and NSPCIL-10
supernatant in vitro
To further investigate the immunosuppressive effects of
NSPCIL-10, we cultivated NSPCIL-10 with MOG35-55-acti-
vated spleen cells isolated from naive 2D2 mice at differ-
ent cell ratios. MOG35-55-activated spleen cells cultivated
with NSPCs or neurobasal medium served as controls.
NSPCIL-10 suppressed proliferation of MOG35-55-acti-
vated cells as determined by 3H-thymidine incorporation,
and production of IL-2 and IFN-γ (Figure 4a). A co-
culture ratio of NSPCIL-10/spleen cells of 1:1 lead to max-
imal inhibition of proliferation and cytokine production,
and a NSPCIL-10/spleen cell ratio of 1:100 still suppressed
proliferation and cytokine production.
To assess whether NSPCs and NSPCIL-10 influence T-
cell activation, we determined the expression of the IL-2
receptor α chain (CD25) on antigen-specific and poly-
clonal stimulation of spleen cells by flow cytometry.
MOG35-55 or ConA-stimulated spleen cells were culti-
vated in the presence of NSPCIL-10, NSPCs or neurobasal
medium. NSPCs and NSPCIL-10 potently suppressed acti-
vation of CD4 T-cells as determined by CD25 expression
(Figure 4b).
To evaluate whether immunosuppression by NSPCs
and NSPCIL-10 is mediated by soluble factors, culture su-
pernatants of NSPCs and NSPCIL-10 were collected and
incubated with antigen-specific or polyclonal stimulation
of spleen cells. Culture supernatants of NSPCs and
NSPCIL-10 inhibited proliferation, and IFN-γ and IL-17
production of ConA-stimulated cells in comparison to
neurobasal medium (Figure 5a,b,c).
Inhibition of T-cell proliferation by NSPCIL-10 is not
mediated by IDO or induction of apoptosis
NSPCIL-10 inhibited T-cell proliferation. T-cell prolifera-
tion depends on the availability of tryptophan, which is
closely regulated by the tryptophan-degrading enzyme
IDO [25]. IDO expression is induced in many cell types,
including macrophages, dendritic cells, fibroblasts,
microglia and astrocytes by the proinflammatory cyto-
kines IFN-γ and IFN-β. We considered whether im-
munosuppression by NSPCIL-10 is related to IDO
activity. In vitro cultivated NSPCIL-10 and NSPCs
expressed large amounts of IDO as demonstrated by
RT-PCR (Figure 6a). Inhibition of IDO by the trypto-
phan analogue 1-MT [26] did not alter the ability of
NSPCIL-10 to inhibit polyclonal T-cell proliferation, indi-
cating that immunosuppression by NSPCIL-10 is not me-
diated by IDO (Figure 6b).
We also examined whether NSPCIL-10 mediated im-
munosuppression by induction of apoptotic cell death.
We found no enhanced induction of apoptotic cell death
in polyclonal stimulation of spleen cells after cultiva-
tion with NSPCIL-10 or NSPCIL-10 culture supernatants
(Figure 6c). We conclude that the immunosuppressive ef-
fects of NSPCIL-10 are not due to enhanced induction of
apoptosis in CNS-specific or polyclonal T-cells.
Discussion
Different sources of somatic stem cells, including neural
progenitor cells [8,27], hematopoietic [28,29] and mes-
enchymal stem cells [30-32], are currently explored for
their immunomodulatory capacity in trauma, stroke,
neurodegenerative diseases and CNS-directed auto-
immunity. NSPCs have the unique ability to migrate dir-
ectly into the damaged brain [6,27,33,34], and cytokines
released by activated cells during the disease process act
as chemoattractants for NSPCs [11,35-37]. We made use
Figure 3 NSPCIL-10 cells reduce proliferation and IFN-γ
production by lymph node cells. 2D2 mice with MOG35-55-
induced EAE received intravenous injections of 1 x 106 NSPCIL-10, NSPCs
or PBS on day 7 after disease induction. Draining lymph node cells were
isolated 7 days after injection and stimulated with MOG35-55 peptide.
(a) Proliferation was determined by 3H-thymidine incorporation, and (b)
IFN-γ, IL-10 and IL-17 production was determined by ELISA. *P <0.05.
NSPCIL-10 versus NSPCs are expressed as mean values with SD from
three independent experiments. ConA, concanavalin A; EAE,
experimental autoimmune encephalomyelitis; ELISA, enzyme-linked
immunosorbent assay; IFN, interferon; IL, interleukin; MOG35-55, myelin
oligodendrocyte glycoprotein aa 35–55; NSPC, neural stem/progenitor
cell; PBS, phosphate-buffered saline.
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of the specific tropism of neural stem cells to deliver IL-
10 into sites of inflammation and neurodegeneration in
an animal model of CNS inflammation. To this end, we
injected IL-10 producing NSPCs in MOG35-55 peptide
immunized mice and observed EAE disease severity, mi-
gration pattern and immune reactions to evaluate the
therapeutic potential of IL-10 producing NSPCs.
Injection of NSPCIL-10 at the time of peripheral T-cell
activation induced a robust reduction of disease severity,
while injection after onset of clinical symptoms did not
significantly alter the disease course. After intravenous
injection, NSPCs and NSPCIL-10 migrated into the CNS,
as well as into peripheral lymph nodes and spleen. These
results indicate that NSPCs are suitable vectors for drug
delivery into the diseased CNS but also migrate to per-
ipheral lymphoid organs. This is consistent with earlier
studies using neural precursor cells [38].
We analyzed the immune reaction defined by prolifer-
ation and cytokine expression of lymph node cells from
MOG35-55 immunized 2D2 mice treated with NSPCIL-10.
NSPCIL-10 suppressed ex vivo proliferation of T-cells iso-
lated during the peak of the disease. Moreover, NSPCIL-10
suppressed production of IFN-γ but not IL-10 by
MOG35-55-specific T-cells, indicating suppression of
Th1-related cytokines. During the induction phase of
EAE, encephalitogenic T-cells migrate from draining
lymph nodes to the spleen and subsequently into the CNS
[39]. Collectively, these results indicate that intravenously
injected NSPCIL-10 suppress EAE by migrating into per-
ipheral lymphoid organs where they inhibit T-cell prolifer-
ation and cytokine production.
This immunosuppressive effect of NSPCIL-10 on im-
mune cells was confirmed in vitro. NSPCIL-10 suppressed
proliferation and IL-2 and IFN-γ production by antigen-
specific and polyclonal stimulation of spleen cells, and
the presence of NSPCIL-10 cells also inhibited expression
of IL2Rα demonstrating reduced T-cell activation. This
inhibitory effect is mediated at least in part by direct
Figure 4 NSPCIL-10 and NSPCs inhibit proliferation and cytokine production by T-cells. (a) C57BL/6 spleen cells were polyclonal-activated
with ConA in the presence of NSPCIL-10 (black squares), NSPCs (open diamonds) or neurobasal medium (open circles) as indicated. Proliferation
was determined by 3H-thymidine incorporation. IFN-γ and IL-2 production was assessed by ELISA. *P <0.05. Mean values are expressed with SD
from three independent experiments. (b) Frequency of CD25+ cells of CD4 T-cells of MOG35-55-stimulated 2D2 spleen cells or ConA-stimulated
spleens cells after cultivation with NSPCIL-10, NSPCs or neurobasal medium. Analysis was performed by flow cytometry. *P <0.05. NSPC, neural
stem/progenitor cell; ConA, concanavalin A; ELISA enzyme-linked immunosorbent assay; IFN, interferon; IL, interleukin; MOG35-55, myelin
oligodendrocyte glycoprotein aa 35–55.
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interaction of NSPCIL-10 and T-cells as it was also ob-
served after mitogen activation of T-cells in the absence
of APCs. In addition, IL-10 could reduce inflammation
by reducing MHC class II expression by APCs.
Other studies have shown similar peripheral immuno-
suppressive effects after peripheral injection of neural
stem cells or neural precursor cells. In these studies,
Figure 5 Supernatant of NSPCIL-10 inhibits proliferation, and the
production of IFN-γ and IL-17 by spleen cells. C57BL/6 spleen
cells were stimulated with ConA in the presence of neurobasal
medium (white bar, circles) or culture supernatant of NSPCIL-10 (black
bar, squares) or NSPC (grey bar, diamonds). (a) Proliferation was
determined by 3H-thymidine incorporation, and production of (b)
IFN-γ and (c) IL-17 was assessed by ELISA. *P <0.05. Mean values are
expressed with SD from three independent experiments. ConA,
concanavalin A; ELISA, enzyme-linked immunosorbent assay; IFN,
interferon; IL, interleukin; NSPC, neural stem/progenitor cell.
Figure 6 Immunosuppression of NSPCIL-10 is not mediated by
IDO and not due to induction of apoptosis. (a) NSPCIL-10 and
NSPCs express IDO. IDO expression was detected by RT-PCR in
spleens, NSPCIL-10 and NSPCs. (b) Inhibition of IDO by 1-MT does
not abrogate the immunosuppression mediated by co-culture of
NSPCIL-10. C57BL/6 spleen cells were activated with ConA in the
presence of neurobasal medium, NSPCIL-10 or NSPCIL-10 and 1-MT.
Proliferation was determined by 3H-thymidine incorporation. (c)
NSPCIL-10 and NSPCIL-10 culture supernatants do not induce apoptosis
in activated spleen cells. C57BL/6 spleen cells were stimulated with
ConA in the presence of medium, NSPCIL-10 and NSPCIL-10 culture
supernatant. After 24 hours, the frequency of PI+ cells was determined
by flow cytometry. 1-MT, 1-methyl-DL-tryptophan; ConA, concanavalin
A; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; NSPC, neural
stem/progenitor cell; PI, propidium iodide; RT-PCR, reverse transcription
polymerase chain reaction.
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intravenously injected neural precursor cells migrated to
peripheral lymphoid organs and inhibited proliferation,
activation or release of proinflammatory cytokines by
autoreactive T-cells [7]. Subcutaneously injected neural
stem cells migrated into lymph nodes and inhibited the
generation of effector T-cells [38]. In our experiments,
disease suppression was maximal when NSPCIL-10 was
injected at the time of peripheral T-cell activation. This
observation further supports the notion that NSPCIL-10
attenuates EAE by inhibiting T-cell activation in periph-
eral lymphoid organs rather than within the CNS.
Non-transfected NSPCs were used as a control in all
experiments. Injection of NSPCs at the time of periph-
eral T-cell activation did not result in reduction of clin-
ical EAE as opposed to injection of NSPCIL-10. Other
studies have previously shown beneficial effects of neural
stem cells or neural precursor cells on EAE disease
course [7,27,33,38]. Differences in EAE models, mouse-
strains, NSPC-types or time points of injection could
contribute to these different results. In this study, the
migration pattern of NSPCs was similar compared to
the pattern of NSPCIL-10 and also comparable to previ-
ous observations. We detected NSPCs in peripheral
lymphoid organs and within the CNS after intravenous
injection similar to our results with NSPCIL-10. We also
found an inhibitory effect on proliferation and IL-2/IFN-
γ production of antigen-specific activated lymph node
cells and spleen cells isolated after 35 days pi, and during
the disease peak. Moreover, NSPCs inhibited prolifera-
tion and IL-2/IFN-γ production of antigen-specific and
polyclonal stimulation of spleen cells in co-cultivation
experiments. Thus, we were able to replicate in vitro ef-
fects of neural stem cells or NSPCs described previously.
However, in contrast to previous studies, we were not
able to show in vivo effects of non-transfected NSPCs.
In general, the inhibitory in vitro effects of NSPCs were
weaker than those of NSPCIL-10.
Another possible mechanism by which NSPCs may in-
hibit immune cells could be the induction of apoptosis.
Previous studies have shown that mesenchymal stem
cells [40] and neural multipotent precursor cells [8] in-
duced apoptosis in activated T-cells. In addition, Yang et
al. [13] demonstrated that IL-10-expressing neural stem
cells induce apoptosis in CD4+ T-cells. In contrast, in
our experiments, NSPCIL-10 or culture supernatants of
NSPCIL-10 did not induce apoptosis of antigen-specific
or polyclonal stimulation of spleen cells. We further in-
vestigated if IDO expression could be responsible for the
inhibitory effects of NSPCIL-10. IDO is the first and rate-
limiting enzyme in the degradation of tryptophan to
kynurenine [41]. In healthy individuals, IDO is expressed
only at low levels but expression increases after infection
or inflammation [25]. It was shown that in proteolipid
protein (PLP)-induced EAE, IDO induction leads to
reduced neuroinflammation [42] and that mesenchymal
stem cells suppress proliferation of T-cells via expression
of IDO [43]. NSPCIL-10 and NSPCs express IDO in cul-
ture as demonstrated by RT-PCR, but there was no asso-
ciation between IDO expression and inhibition of
proliferation mediated by NSPCIL-10.
IL-10 is an anti-inflammatory cytokine mainly pro-
duced by Th2 cells, and inhibits the activity of Th1 lym-
phocytes, natural killer (NK) cells and macrophages [16].
The inhibitory effects of IL-10 may be mediated by in-
hibition of the co-stimulatory signals CD80 and CD86
on APCs [44], or by induction of immunosuppressive
regulatory T-cells (Tregs), such as Tr1, which in turn in-
hibit cell proliferation through production of IL-10 or
transforming growth factor (TGF)-β [45]. In addition, it
has previously been shown that stimulation of CD4+ T-
cells in the presence of IL-10 induces a state of unre-
sponsiveness with reduced proliferation and IL-2 pro-
duction [46]. Our co-cultivation experiments using
NSPCIL-10 showed that there was no decreased expres-
sion of CD80 or CD86 on antigen-specific stimulated
spleen cells or a higher percentage of CD4+ FoxP3+ cells
(data not shown), but we found reduced expression of
IL2Rα, reduced IL-2 production and proliferation when
spleen cells were stimulated in the presence of NSPCIL-10.
Therefore, IL-10 producing NSPCs seem to mediate their
effects by inducing a non-responsive state in T-cells. In a
recent study, Yang et al. [13] evaluated the effects of IL-10
producing neural stem cells on EAE. After intravenous
injection, cells were detected in peripheral lymphoid
organs and were shown to act via an immunosuppressive
mechanism which was enhanced through IL-10 produc-
tion. In contrast to our study, these experiments also
showed a positive effect when cells were injected after
onset of clinical EAE.
As proof of concept, we have shown that IL-10 produ-
cing NSPCs ameliorate the clinical disease course of
EAE. NSPCs may be used as vehicles to transport immu-
nomodulatory molecules to sites of T-cell activation and
inflammation in order to attenuate autoimmune pro-
cesses. These results, however, do not rule out immuno-
modulatory functions of NSPCIL-10 within the brain and
further work is needed to explore this. The finding that
NSPCIL-10 only marginally suppresses EAE disease sever-
ity when administered after EAE symptoms has been
established and indicates that the time of administration
of NSPCIL-10 critically determines its potency to sup-
press CNS autoimmunity. Whether such an approach
would be feasible in patients with MS remains to be
established.
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